MX2023001296A - Composiciones y metodos para tratar enfermedades y trastornos. - Google Patents
Composiciones y metodos para tratar enfermedades y trastornos.Info
- Publication number
- MX2023001296A MX2023001296A MX2023001296A MX2023001296A MX2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A MX 2023001296 A MX2023001296 A MX 2023001296A
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- methods
- compositions
- treating diseases
- diseases
- Prior art date
Links
- 208000037765 diseases and disorders Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063060413P | 2020-08-03 | 2020-08-03 | |
| US202063115312P | 2020-11-18 | 2020-11-18 | |
| PCT/US2021/030192 WO2022031330A1 (en) | 2020-08-03 | 2021-04-30 | Compositions and methods for treating diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001296A true MX2023001296A (es) | 2023-02-22 |
Family
ID=80117618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001296A MX2023001296A (es) | 2020-08-03 | 2021-04-30 | Composiciones y metodos para tratar enfermedades y trastornos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230310444A1 (enExample) |
| EP (1) | EP4188368A4 (enExample) |
| JP (1) | JP2023537477A (enExample) |
| KR (1) | KR20230048358A (enExample) |
| CN (1) | CN116419752A (enExample) |
| AU (1) | AU2021321350A1 (enExample) |
| BR (1) | BR112023001861A2 (enExample) |
| CA (1) | CA3188171A1 (enExample) |
| CU (1) | CU20230009A7 (enExample) |
| IL (1) | IL300310A (enExample) |
| MX (1) | MX2023001296A (enExample) |
| WO (1) | WO2022031330A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| EP4319750A4 (en) | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
| WO2023172640A1 (en) * | 2022-03-08 | 2023-09-14 | X4 Pharmaceuticals, Inc. | Treatments for single-mutant waldenström's macroglobulinemia |
| JP2025516501A (ja) * | 2022-05-11 | 2025-05-30 | キュリス，インコーポレイテッド | Ｉｒａｋ４修飾化合物による疾患及び障害の治療 |
| WO2024027750A1 (en) * | 2022-08-02 | 2024-02-08 | Beigene Switzerland Gmbh | Methods of treating pulmonary hypertension using btk inhibitors |
| WO2025208000A1 (en) * | 2024-03-29 | 2025-10-02 | Curis, Inc. | Methods of treating cancer in patients with altered protein expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3466955T (lt) * | 2014-01-13 | 2021-02-25 | Aurigene Discovery Technologies Limited | Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas |
| TW201701879A (zh) * | 2015-04-30 | 2017-01-16 | 拜耳製藥公司 | Ｉｒａｋ４抑制劑組合 |
| US20170035881A1 (en) * | 2015-10-19 | 2017-02-09 | Acerta Pharma B.V. | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor |
| EP3600270B1 (en) * | 2017-03-31 | 2023-06-14 | Aurigene Oncology Limited | Compounds and compositions for treating hematological disorders |
| HUE067356T2 (hu) * | 2017-10-31 | 2024-10-28 | Curis Inc | IRAK4 inhibitor és BCL-2 inhibitor kombinációban, rák kezelésére való felhasználásra |
| EP3800188A1 (en) * | 2019-10-02 | 2021-04-07 | Bayer AG | Substituted pyrazolopyrimidines as irak4 inhibitors |
| MX2023005591A (es) * | 2020-11-18 | 2023-05-29 | Curis Inc | Metodos de tratamiento de enfermedades y trastornos. |
| EP4319750A4 (en) * | 2021-04-08 | 2025-02-26 | Curis, Inc. | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
-
2021
- 2021-04-30 IL IL300310A patent/IL300310A/en unknown
- 2021-04-30 CA CA3188171A patent/CA3188171A1/en active Pending
- 2021-04-30 BR BR112023001861A patent/BR112023001861A2/pt unknown
- 2021-04-30 CN CN202180057734.1A patent/CN116419752A/zh active Pending
- 2021-04-30 JP JP2023507267A patent/JP2023537477A/ja active Pending
- 2021-04-30 KR KR1020237007466A patent/KR20230048358A/ko active Pending
- 2021-04-30 CU CU2023000009A patent/CU20230009A7/es unknown
- 2021-04-30 EP EP21852519.4A patent/EP4188368A4/en active Pending
- 2021-04-30 AU AU2021321350A patent/AU2021321350A1/en active Pending
- 2021-04-30 MX MX2023001296A patent/MX2023001296A/es unknown
- 2021-04-30 WO PCT/US2021/030192 patent/WO2022031330A1/en not_active Ceased
- 2021-04-30 US US18/019,400 patent/US20230310444A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230310444A1 (en) | 2023-10-05 |
| BR112023001861A2 (pt) | 2023-03-07 |
| CA3188171A1 (en) | 2022-02-10 |
| CN116419752A (zh) | 2023-07-11 |
| CU20230009A7 (es) | 2023-09-07 |
| WO2022031330A1 (en) | 2022-02-10 |
| EP4188368A4 (en) | 2024-09-04 |
| JP2023537477A (ja) | 2023-09-01 |
| KR20230048358A (ko) | 2023-04-11 |
| AU2021321350A1 (en) | 2023-03-16 |
| EP4188368A1 (en) | 2023-06-07 |
| IL300310A (en) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| MX2025003876A (es) | Compuestos para el tratamiento de enfermedades mediadas por alfa-1 antitripsina | |
| EP4374858A3 (en) | Benzimidazolone derived inhibitors of bcl6 | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| MX2022016422A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| EP4371562A3 (en) | 2-quinolone derived inhibitors of bcl6 | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| WO2019224790A3 (en) | Prodrugs of fulvestrant | |
| PH12022550491A1 (en) | Perk inhibiting pyrrolopyrimidine compounds | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| PH12022550497A1 (en) | Perk inhibiting compounds | |
| WO2019078968A3 (en) | Cyclic compounds as immunomodulating agents | |
| MX2019013562A (es) | Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos. | |
| EP4357334A3 (en) | Conjugated oligonucleotide compounds, methods of making and uses thereof | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| PH12021552680A1 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases | |
| ZA202206266B (en) | Pd-l1 antagonist compound |